Lonza Group stock gains focus after Merck CDMO deal

Published on 11/04/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza Group stock is in focus after the company agreed to buy five Merck CDMO sites in the United States. The deal expands its production network.

Deal expands Lonza's US platform

Lonza agreed to acquire five Merck CDMO sites and about 1,100 employees.
The transaction would expand Lonza's US CDMO network from four to nine sites.
Closing is expected in mid-2027, subject to customary conditions.

Lonza Group, CH0013841017, Illustration mit AI erstellt.

Lonza Group stock traded at 721.70 euros on Lang & Schwarz at 17:05 CET on Wednesday, November 4, 2026. That compares with 686.80 euros in the previous report dated October 27, an increase of 5.08 percent.

The latest business development is Lonza's agreement, announced on November 3, to acquire five contract development and manufacturing organization sites from Merck KGaA. The Deutsche Börse announcement said the assets cover sites in Missouri, Wisconsin, California and Indiana.

More US capacity and capabilities

The acquisition would increase Lonza's US CDMO footprint from four to nine sites and add about 1,100 employees. The company said its US workforce would exceed 6,000 after the transaction, strengthening services for bioconjugates, payload-linkers, viral vectors, lipid nanoparticles and related technologies.

For full-year 2028, Lonza expects the acquired sites to contribute around CHF 250 million in sales. Their CORE EBITDA margin is expected to be below Lonza's level initially, while the group said the impact on consolidated results would be insignificant. Lonza expects the assets to reach the group's future margin level by the mid-2030s.

Completion remains ahead

Closing is expected in mid-2027 and remains subject to customary conditions. Until completion, the businesses will continue to operate independently. Lonza said the purchase will be funded with cash on hand and existing credit facilities and will not affect its previously announced share buyback after the Capsules & Health Ingredients divestment.

Investors can follow the real-time quote of Lonza Group stock for the latest market indication.

The Swiss equity market is represented by the SMI, providing the broader backdrop for Swiss-listed shares.

More updates are available in more news and analyses on Lonza Group stock.